Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
The world of cancer diagnostics is entering an era of remarkable growth, with accelerated advancements and heightened market activity. A comprehensive new research publication, now available, offers an in-depth analysis and forecast on how these changes are shaping the market for molecular diagnostics in oncology from 2023 to 2027.
At the forefront, the report delves into the dynamism fueled by trends such as the ascendancy of personalized medicine, the critical role of pharmacogenomics, the disruptive impact of liquid biopsies, and the precision of minimal residual disease testing. Highlighting the transformative effect of Cancer Companion Diagnostics, the research emphasizes its burgeoning presence and influence across the market landscape.
The study projects a significant surge in demand for molecular diagnostics, propelled by the convergence of state-of-the-art companion diagnostics and the increased capacity of labs to cater to a global patient base. Driving this momentum are diagnostic advancements that steadily displace traditional physician diagnostics with cutting-edge, intelligent diagnostic tests.
With precision and detailed segmentation, the report analyzes market variations by cancer type and diagnostic products, alongside geographical breakdowns that offer insights into 18 key countries and 4 major regions worldwide. It is equipped with hundreds of pages of data, including comprehensive lists of Current United States Medicare Fee Payment Schedules, to aid in-depth understanding of test pricing and market valuation.
Researchers, analysts, healthcare planners, and industry executives will find the report an invaluable resource for strategic planning, investment decisions, and forecasting demand for novel testing technologies and regimes. It offers an extensive review of the evolving market scenarios, providing stakeholders with crucial insights for informed decision-making and strategic positioning within the global cancer molecular diagnostics landscape.
Molecular diagnostics has become a key area in the cancer care continuum, with technological innovations offering nuanced perspectives on patient-specific therapeutic approaches. The current analysis integrates these technological shifts with market demand, crafting a comprehensive viewport for entities involved in enhancing and expanding clinical diagnostics facilities.
This rigorous analytical work is expected to sharpen the competitive edge of laboratories and hospitals by equipping them with targeted forecasts and growth estimation for new technology tests across various regions. The data laid out in this report holds the potential to underpin the future of cancer diagnostics, guiding the industry toward a more accurate, personalized, and cost-effective era in cancer care.
Clinicians, lab managers, diagnostic companies, and stakeholders in the healthcare and diagnostics sectors are thereby encouraged to explore the findings and projections detailed in this latest publication.
Key Topics Covered:
- Market Insights and Trends
- Analysis of Key Market Insights
- Emerging Trends Driving Market Growth
- Market Segmentation and Regional Analysis
- Breakdown by Market Segments
- Regional Market Analysis and Trends
- Key Players and Competitive Landscape
- Overview of Key Industry Players
- Competitive Strategies and Market Positioning
- Future Outlook and Opportunities
- Growth Opportunities in the Market
- Forecast and Predictions for Future Market Trends
- Drivers, Restraints, Opportunities, and Challenges
- Factors Influencing Market Dynamics
- Opportunities and Challenges Ahead
Companies Mentioned
- 10x Genomics, Inc.
- Abbott Laboratories
- AccuraGen Inc.
- Adaptive Biotechnologies
- Aethlon Medical
- Agilent/Dako
- Anchor Dx
- ANGLE plc
- ARUP Laboratories
- AVIVA Systems Biology
- Baylor Miraca Genetics Laboratories
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- BGI Genomics CoLtd
- BillionToOne
- Bioarray Genetics
- Biocartis
- Biocept, Inc.
- Biodesix Inc.
- BioFluidica
- BioGenex
- BioIVT
- Biolidics Ltd
- bioMérieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- Bio-Reference Laboratories
- Bio-Techne
- Bioview
- Bolidics
- Boreal Genomics
- Bristol-Myers Squibb
- Burning Rock
- Cardiff Oncology
- Caris Molecular Diagnostics
- Castle Biosciences, Inc.
- Celemics
- CellCarta
- CellMax Life
- Cepheid (Danaher)
- Charles River Laboratories
- Circulogene
- Cizzle Biotech
- Clinical Genomics
- Cytolumina Technologies Corp.
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Diasorin S.p.A.
- Dxcover
- Enzo Biochem
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Exact Sciences
- Fabric Genomics
- Fluxion Biosciences
- Freenome
- FUJIFILM Wako Diagnostics
- Fulgent Genetics
- Fyr Diagnostics
- GeneFirst Ltd.
- Genetron Holdings
- GenomOncology
- GILUPI Nanomedizin
- Guardant Health
- HansaBiomed
- HeiScreen
- Helomics
- HTG Molecular Diagnostics
- iCellate
- ICON PLC
- Illumina
- Incell Dx
- Inivata
- INOVIQ
- Integrated Diagnostics
- Invitae Corporation
- Invivogen
- Invivoscribe
- Janssen Diagnostics
- Lunglife AI Inc
- MDNA Life SCIENCES, Inc.
- MDx Health
- Menarini Silicon Biosystems
- Mesa Laboratories, Inc.
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Myriad Genetics/Myriad RBM
- NantHealth, Inc.
- Natera
- NeoGenomics
- NGeneBio
- Novogene Bioinformatics Technology Co., Ltd.
- Oncocyte
- OncoDNA
- Ortho Clinical Diagnostics
- Oxford Nanopore Technologies
- PamGene
- Panagene
- Perkin Elmer
- Personal Genome Diagnostics
- Personalis
- Precipio
- Precision Medicine Group
- PrecisionMed
- Predicine
- Promega
- Qiagen
- Rarecells SAS
- RareCyte
- Roche Molecular Diagnostics
- Screencell
- Sema4 Holdings
- Sense Biodetection
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc.
- Singulomics
- SkylineDx
- Standard BioTools
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific Inc.
- Todos Medical
- Variantyx
- Veracyte
- Volition
- Vortex Biosciences
- Vyant Bio
- Zhejiang Orient Gene Biotech
For more information about this report visit https://www.researchandmarkets.com/r/n9kxcm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
